Related Experiment Video
Updated: Sep 10, 2025

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry
Published on: July 13, 2019
Therapeutic potential of flavonols in the treatment of JCPyV
Evan MacLure1, Kaitlin Garabian1, Bethany A O'Hara1
1Department of Cell Biology, Biochemistry, and Molecular Biology, Brown University, Providence, Rhode Island, USA.
Abstract:
JC polyomavirus (JCPyV) is a double-stranded DNA virus that causes progressive multifocal leukoencephalopathy (PML), a demyelinating disease with a high rate of morbidity and mortality. There are limited treatment options for patients diagnosed with PML, and most involve reconstitution of immunological functions. In this paper, we show that flavonols, specifically quercetin, myricetin, and fisetin, significantly reduce JCPyV infection in human glial cells. We further show that quercetin and fisetin can suppress viral spread in an already established infection, suggesting therapeutic viability of these drugs as antivirals. Additional research is required to determine the mechanism of action of flavonols in inhibiting JCPyV infection and to investigate whether these compounds have the potential to cross the blood-brain barrier in significant amounts to inhibit the virus in the brain parenchyma.IMPORTANCEThe human polyomavirus, JC polyomavirus (JCPyV), causes significant morbidity and mortality in immunosuppressed or immunomodulated patients. There are no approved antivirals to treat JCPyV-induced disease. Flavonols are naturally occurring polyphenolic compounds that are known to antagonize pathways involved in JCPyV infection. Several flavonols were found to inhibit initial JCPyV infection and viral spread in a glial cell line and in normal human glial cells. These represent a promising new treatment paradigm for patients at risk of suffering from JCPyV-induced disease.
Insights
Flavonols like quercetin show promise in fighting JC polyomavirus (JCPyV) infection, which causes the deadly PML disease. These compounds inhibit viral entry and spread in human glial cells, offering potential new antiviral therapies.
Area of Science:
- Virology
- Neuroscience
- Pharmacology
Background:
- JC polyomavirus (JCPyV) causes progressive multifocal leukoencephalopathy (PML), a severe demyelinating disease.
- Current PML treatments are limited, often focusing on immune reconstitution.
- There are no approved antiviral drugs specifically for JCPyV-induced disease.
Purpose of the Study:
- To investigate the antiviral potential of flavonols against JCPyV infection.
- To determine if flavonols can inhibit both initial JCPyV infection and viral spread.
Main Methods:
- Treatment of human glial cells with specific flavonols (quercetin, myricetin, fisetin).
- Assessment of JCPyV infection levels and viral spread following flavonol treatment.
- In vitro studies using glial cell lines and normal human glial cells.
Main Results:
- Quercetin, myricetin, and fisetin significantly reduced JCPyV infection in human glial cells.
- Quercetin and fisetin demonstrated efficacy in suppressing viral spread in established infections.
- Flavonols inhibited both initial JCPyV infection and subsequent viral dissemination.
Conclusions:
- Flavonols represent a promising new class of therapeutic agents against JCPyV.
- Quercetin and fisetin show potential as viable antiviral drugs for PML.
- Further research is needed to elucidate the mechanism of action and blood-brain barrier penetration.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease IV: Preventive Measures
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Coronary Artery Disease I: Introduction

